Trump speaks against socialism, but his drug price control plan says otherwise

9 March 2019

US President Donald Trump recently promised a cheering Miami crowd that America "will never be a socialist country." Let's hope!, writes Institute for Policy Innovation (IPI) resident scholar Dr Merrill Mathews.

But some of his top officials at the Department of Health and Human Services (DHSS) apparently didn't get the memo. They’re forging ahead with a plan to impose price controls in Medicare.

Many seniors, numerous patient advocacy groups, and most free market economists and health policy experts strongly oppose the proposal, which would deprive American patients of lifesaving medications and stifle medical innovation. President Trump should tell his officials to stand down, said Dr Mathews.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK